[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Assistance Publique - Hôpitaux de Paris\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":682},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,894,0,25,[9,44,73,98,123,144,171,200,227,257,281,307,341,368,392,417,441,467,496,522,566,594,618,640,662],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100504144","phase-3-tadalafil-for-severe-pulmonary-hypertension-due-to-chronic-obstructive-pulmonary-disease-100504144",false,"NCT05844462","Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease","Efficacy of Phosphodiesterase Type 5 Inhibitors in Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease","ERASE PH-COPD","Inclusion Criteria:\n\n* Patients ≥ 18 and \\\u003C85 years at inclusion,\n* Dyspnea WHO functional class II to IV,\n* Severe precapillary pulmonary hypertension defined by :\n\n  * a mean pulmonary artery pressure (mPAP) \\>20\n  * associated with normal pulmonary artery wedge pressure (PawP ≤15 mmHg)\n  * and pulmonary vascular resistance (PVR) \\>5 WU\n* COPD diagnosed according to current international recommendation with persistent airflow limitation defined by post-bronchodilatator Forced expiratory volume in 1 second (FEV1) \u002F forced vital capacity (FVC): FEV1\u002FFVC \\\u003C 0.70,\n* Naive patients from PDE5i (sildenafil, tadalafil) PH treatments and who did not receive other specific PH treatment in the last 3 months (bosentan, ambrisentan, macitentan, riociguat, epoprostenol, treprostinil, iloprost),\n* Treatments for COPD need to be stable for at least 1 month before screening visit,\n* Patients who fulfill criteria for a supplemental long-term oxygen therapy need to be supplied sufficiently before study entry. The amount of supplemental oxygen and the delivery method need to be stable for at least 1 month before screening visit,\n* Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period,\n* Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures,\n* Affiliation to a social security regime,\n\nExclusion Criteria:\n\n* Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator,\n* Patients with underlying medical disorders and anticipated life expectancy below 12 months (eg active cancer disease with localized and\u002For metastasized tumor mass),\n* PH not due to chronic respiratory diseases (group 1, 2, 4 or 5 of the clinical classification of PH),\n* Other respiratory diseases: interstitial lung disease, sarcoidosis, lymphangioleiomyomatosis, histiocytosis, or untreated severe sleep apnea disorders,\n* 6-minutes walk distance \\\u003C 50 m or patients unable to perform the 6-minutes walk test,\n* Exacerbation of the COPD requiring hospitalization in the last 8 weeks before screening,\n* COPD with mild (\\> 80% predicted value) or severe (FEV1 \\\u003C30% predicted value) airflow limitation,\n* Patients listed for lung transplantation at the time of inclusion,\n* Systolic left ventricular dysfunction with left ventricular ejection fraction \\\u003C40% on echocardiography,\n* Patient on AME (state medical aid),\n* Participation in another clinical trial during the preceding 3 months and during the study,\n* Pregnant women, or breast-feeding women, or women with childbearing potential not using a combination of condoms and a safe and highly effective contraception method (hormonal contraception with implants or oral contraceptives, or intrauterine devices) and one month after the end of the study, WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal \\[defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level \\> 35 mIU\u002FmL\\],\n* Patient under guardianship or curatorship\n\nNon-inclusion criteria related to treatment by tadalafil:\n\n* Contraindication to tadalafil:\n\n  * Severe renal failure (creatinine clearance \\\u003C 30 mL\u002Fmin\u002F1,73 m2)\n  * Severe liver cirrhosis Child-Plugh C\n  * Severe systemic hypotension \\\u003C90\u002F50\n  * Recent myocardial infarction \\\u003C90 days\n  * Medical history of anterior ischemic optic neuropathy\n  * Hypersensitivity to tadalafil or any of the excipients\n* Concomitant use of potent CYP3A4 inhibitors or inducers, soluble guanylate cyclase stimulator (riociguat), other PDE5 inhibitors or nitrates or doxazosin\n* Cardiovascular diseases:\n\n  * Clinically significant aortic and mitral valve disease\n  * Pericardial constriction\n  * Restrictive or congestive cardiomyopathy\n  * Significant left ventricular dysfunction\n  * Life-threatening arrhythmias\n  * Symptomatic coronary artery disease\n  * Uncontrolled hypertension.\n  * Angulation of the penis, cavernosal fibrosis, Peyronie's disease or history of priapism\n* Pulmonary or upper respiratory infection requiring antibiotics, or pulmonary embolism in the last 4 weeks before screening\n* Participation in a respiratory rehabilitation program within the 4 weeks prior to screening or scheduled during the study period\n* Right heart failure necessitating catecholamine support within the 4 weeks prior to screening.","ALL","18 Years","85 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","ERASE PH-COPD is a randomized double-blind study, with 2 parallel groups. Patients with severe pulmonary hypertension due to chronic obstructive pulmonary disease, will be randomly assigned to receive Tadalafil orally or placebo.",[29,30],"Pulmonary Hypertension","Chronic Obstructive Pulmonary Disease","RECRUITING","2026-08-19",{"date":34,"type":35},"2026-08-20","ACTUAL",{"date":37,"type":35},"2024-02-01",{"date":39,"type":23},"2027-12",{"name":41,"class":42},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100652685","use-of-connected-glasses-to-help-the-communication-of-non-temporarily-speaking-patients-in-intensive-care-unit--a-pilot-study-100652685","NCT07776795","Use of Connected Glasses to Help the Communication of Non Temporarily Speaking Patients in Intensive Care Unit : a Pilot Study","CASTOR-REA","Inclusion Criteria:\n\n* Adult patients hospitalized in the Intensive Care Medicine Department of the Tenon Hospital, whatever their reason for admission to the department\n* Neuropsychiatric state compatible with the development of a coherent dialogue: good vigilance attested by a RASS -1 to +1 (Richmond Agitation Sedation Scale), no confusion attested by a negative CAM-ICU test (Confusion Assessment Method for the Intensive Care Unit), no sedative treatment or light sedative treatment\n* Physically unable to communicate verbally for a foreseeable period of at least 48 hours, which may be linked to invasive mechanical ventilation (with endotracheal tube or tracheotomy without phonatory cannula) or to a speech and\u002For phonation disorder whatever the cause (eg: after-effects of ENT surgery, laryngeal oedema, etc.).\n* Have expressed no objection to participating in the study.\n\nExclusion Criteria:\n\n* Neuropsychiatric state incompatible with the development of a coherent dialogue: agitation (RASS ≥ 2) or somnolence (RASS ≤ -2), confusion (CAM-ICU positive)\n* Simple, fluid appropriation by the patient of the slate as a communication tool : no motor deficit of the dominant upper limb, no graphic problems, no language barrier\n* Inability of patient to use connected glasses: blindness, eye conditions preventing eye opening, vision disorders without corrective lenses available, known patent cognitive disorders, mental retardation",{"count":52,"type":23},30,"OBSERVATIONAL","Hospitalization in an intensive care unit (ICU) is accompanied by major physical and emotional stress for patients, a source of discomfort and a risk factor for post-resuscitation syndrome. Efficient patient-caregiver and patient-family communication is needed to: understand the patient's symptoms in order to relieve them, understand the patient's primary needs, understand the patient's questions and concerns in order to respond to them, rehumanize our care and re-establish a more balanced relationship with the patient. However, communication with the patient is often limited, due for example to invasive mechanical ventilation: it is estimated that half of intubated patients meet basic communication criteria (calm patient responding to simple commands and verbal requests) after 2 days of mechanical ventilation, without however being able to express themselves verbally.\n\nAugmentative and alternative communication tools exist, ranging from pictograms and slates to voice synthesizers, and are used in ICU. The critical care departments of the University Hospitals of Marseille and Tours use a communication interface consisting of a mobile screen with eye tracking for vigilant patients unable to communicate verbally, which seems to have been appreciated by patients and their families, although its effect has not been measured.\n\nConnected glasses are one of the tools available. These are pairs of glasses fitted with infrared sensors that detect a signal predefined with the patient (such as a wink) and thus enable a tablet with customized communication software to be clicked on and navigated. Potential advantages over eye tracking, which has already been used in critical care departments, include: use in low-light conditions, smaller size (no need for an arm to adjust screen orientation), less concentration (eye tracking requires precise, sustained eye fixation).\n\nThe objective is to conduct a pilot study to assess the feasibility of using this tool in non temporarily speaking patients hospitalized in ICU.",[56,57,58,59],"Mechanical Ventilation","Critical Care, Intensive Care","Artificial Respiration","Communication Aids",[61,62,63,64],"Respiration","artificial","Communication aids for disabled","Augmentative and alternative communications systems","NOT_YET_RECRUITING","2026-08-17",{"date":34,"type":35},{"date":69,"type":23},"2026-10",{"date":71,"type":23},"2028-05",{"name":41,"class":42},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":53,"phases":4,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100652507","immunomonitoring-of-circulating-immune-cells-in-maxillofacial-surgery-100652507","NCT07772063","Immunomonitoring of Circulating Immune Cells in Maxillofacial Surgery","MMUNOFACE: Immunomonitoring of Circulating Immune Cells in Maxillofacial Surgery","IMMUNOFACE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* managed in the department of maxillofacial surgery (Pitié-Salpêtrière Hospital)\n* Scheduled for surgery as part of treatment involving free flap reconstruction\n* Informed about the study, with no objections, and having provided written consent for genetic testing\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Individuals under legal protective measures",{"count":82,"type":23},60,"2 Months","The immune response following facial reconstruction may help predict healing time and the date of discharge after maxillofacial surgery. Regulatory T cells (Tregs) are emerging as powerful modulators of the immune response in various contexts during reconstruction. Indeed, Tregs are involved in tissue regeneration, control the local inflammatory response, and promote effective tissue repair while limiting fibrosis. An early increase in circulating Tregs could serve as an indicator of a favorable reparative\u002Fregenerative response.\n\nPrimary objective: To identify changes in the proportion of regulatory T cells (Tregs) among circulating immune cells between the preoperative and postoperative periods, and to assess its association with length of hospital stay.\n\nPrimary outcome measure: proportion of regulatory T cells (Tregs) among CD4 lymphocytes, measured by flow cytometry at different time points (preoperative, perioperative, and postoperative), and its association with length of hospital stay (days).\n\nStudy Design: monocentric, including a maximum of 60 patients;\n\nInclusion criteria: Age ≥ 18 years; managed in the department of maxillofacial surgery (Pitié-Salpêtrière Hospital); Scheduled for surgery as part of treatment involving free flap reconstruction; Informed about the study, with no objections, and having provided written consent for genetic testing\n\nExclusion criteria: Pregnant or breastfeeding women; Individuals under legal protective measures\n\nResearch Process:\n\nAfter verifying eligibility criteria, patients will be informed about the study during a clinical visit. Following a reflection period that the patient deems necessary to make a decision, their lack of objection and consent to genetic testing will be obtained. As part of the research, a 7 mL tube of ACD blood will be collected in addition to the routine blood samples during routine blood draws at the following visits: preoperative, perioperative (during surgery), and postoperative follow-ups (Day 2, Day 5, and Day 15). These tubes will then be analyzed in the Immunology Research Laboratory of Prof. Miyara and Dr. Bouaoud (CIMI, Pitié Salpêtrière) using flow cytometry (counting\u002Fassay of Tregs and subpopulations). During the operation, surgical waste (bone, muscle, drainage fluids) will also be collected for research purposes; it will be analyzed in the immunology research laboratory of Prof. Miyara and Dr. Bouaoud (CIMI, Pitié Salpêtrière) using flow cytometry and, in some cases, single-cell transcriptomics when the sample meets the necessary quality criteria (sufficient cell count, viability, etc.).",[86,87,88],"Head and Neck Cancer (H&N)","Trauma Sequelae","Osteoradionecrosis of Jaws",[90,91],"Immunomonitoring of Circulating Immune","Cells Following Free Flap Reconstruction in Maxillofacial Surgery",{"date":32,"type":35},{"date":94,"type":23},"2026-09",{"date":96,"type":23},"2027-05",{"name":41,"class":42},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":43},"100539989","safety-registry-of-a-fecal-microbiota-transplant-cohort-100539989","NCT06311006","Safety Registry of a Fecal Microbiota Transplant Cohort","Safety Registry of a Fecal Microbiota Transplant Cohort (COSMIC-FMT)","COSMIC-FMT","Inclusion Criteria:\n\nPatients :\n\n* Adult patient with an indication for FMT for CDI (severe refractory CDI, recurrent CDI);\n* Informed written consent\n\nDonors:\n\n* Adult (18 years or older)\n* Informed Written consent\n\nExclusion Criteria:\n\n* insufficient level of understanding of written and spoken French language",true,{"count":108,"type":23},305,"Clostridium difficile infection (CDI) is a major cause of infectious diarrhea and the most important cause of nosocomial diarrhea. Recurrent forms are a major problem with this infection. The use of fecal microbiota transplantation (FMT), FMT appears in the most recent European and North American recommendations.\n\nThere is no cohort or multicenter registry in France prospectively collecting FMTs, the methods used, their efficacy and side effects. Likewise, there is no prospective collection focused on the cohort of stool donors. A large national cohort of patients who have undergone FMT as part of routine care as well as donors, is essential for evaluating the safety of FMT.",[111],"Clostridium Difficile Infections",[113,114],"Clostridium Difficile Infection","Fecal microbiota transplantation","2026-08-14",{"date":117,"type":35},"2026-08-18",{"date":119,"type":35},"2021-01-04",{"date":121,"type":23},"2029-01-04",{"name":41,"class":42},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":43},"100506772","melatonin-and-response-to-lithium-100506772","NCT05878730","Melatonin and Response to Lithium","A Case-control Study Comparing Melatonin Nocturnal Secretion Between Lithium Responders Versus Non Responders in Type 1 Bipolar Disorder.","MeLiR","Inclusion Criteria:\n\n* BD-1 as defined by DSM-5\n* Age : 18 to 70\n* Current treatment by lithium for more than one year\n* Euthymia defined by : MADRS \\\u003C8 and YMRS \\\u003C8 at inclusion ; no hospitalization or change in mood-stabilizing treatment in the previous 3 months\n* Health condition compatible with blood and urinal sampling\n* Being affiliated to french social security\n* Written consent\n\nExclusion Criteria:\n\n* Treatment by : melatonin, agomelatin, benzodiazepines or hypnotic in the last 15 days\n* Treatment by a strong CYP1A2 inducer in the last month : ciprofloxacine, dihydralazine, fluvoxamine, norfloxacine\n* Current substance use disorder except for tobacco\n* Chronic renal failure with glomerular filtration rate \\\u003C60mL\u002Fmin\n* Jetlag in the last 15 days or life-event impacting circadian rhythmicity (birth, grief, night-work...)\n* Sleep disorders such as Obstructive Sleep-Apnea, restless leg syndrome, narcolepsy\n* Pregnancy, breastfeeding\n* Guardianship\n* Inability to understand french, illiteracy","70 Years",{"count":82,"type":23},"Bipolar disorders are mental illnesses characterized by the recurrence of mood-episodes, that can have a severe impact on the life of individuals. The effect of lithium, one of the main medications used to treat acute episodes or prevent them from happening, is very different from one individual to an-other. So far, there is no way to predict in advance for whom patient this treatment will be effective or for whom it will not.\n\nFinding markers that can predict as early as possible the efficiency of this treatment is a major field of current research in psychiatry, in order to avoid maintaining an inefficient treatment for several years that can have negative side-effects.\n\nOver the past decades, it has been shown by multiple studies that lithium can act on the biological clock, that regulates circadian rhythmicity of the body (i.e. rhythms that presents a 24 hours periods, such as rhythms of sleep and activity, feeding, social activities...). But it is still very unclear whether the effect of lithium in regulating the mood in bipolar disorders is mediated by this action.\n\nMelatonin is one of the key-regulator of circadian rhythmicity of the human body. Our hypothesis, based on some previous studies, is that the action of lithium in type-1 bipolar disorder (BD-I) is related to an action on melatonin secretion.\n\nTo test that, we want in this study to compare the noctunal secretion of melatonin between BD-I individuals with a good response to lithium versus with a poor response to lithium.",[135],"Bipolar Disorder I",[137],"lithium",{"date":117,"type":35},{"date":140,"type":35},"2023-07-26",{"date":142,"type":23},"2026-12",{"name":41,"class":42},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":43},"100651773","long-term-psychological-and-cognitive-evaluation-of-children-treated-with-allogeneic-hematopoietic-stem-cell-transplantation-for-immunodeficiency-100651773","NCT07766304","Long-term Psychological and Cognitive Evaluation of Children Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Immunodeficiency","PSY-DIP","Inclusion Criteria:\n\n* Patients who underwent allogeneic transplantation for a primary immunodeficiency at Necker Hospital, regardless of the genetic diagnosis, and at least 2 years post Allogeneic hematopoietic stem cell transplantation.\n* Chronological age at the time of evaluation between 6 years and 8 years 11 months.\n* Holders of parental authority and children or adolescents or adults' patients informed and consenting to participate in the study\n\nExclusion Criteria:\n\n* Child transplanted for a condition other than the primary immunodeficiency or at a different center.\n* Presence of an associated acquired or genetic neurological condition, independent of the PID, likely to significantly impair cognitive development.\n* Severe uncorrected sensory impairment (auditory or visual) rendering the cognitive assessment uninterpretable.\n* Refusal to participate by the child or those with parental authority.\n* Child not fluent in French or not proficient enough in French to complete the cognitive tests and questionnaires.\n* Profound intellectual disability.","6 Years","8 Years",{"count":52,"type":23},"Primary immunodeficiencies (PIDs) are a large group of genetic diseases of the immune system with highly variable clinical presentations. Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the treatments offered to some patients with PIDs. It is a curative but particularly demanding treatment, potentially life-threatening, requiring several months of hospitalization, prolonged limitations in social interactions for the patient, and impacting the entire family unit. The short-term complications of HSCT are numerous and well-known. However, few studies describe the long-term psychological and cognitive complications of HSCT, particularly in the context of PIDs. The few published studies in children concern patients transplanted for hematological malignancies, a context very different from that of primary immunodeficiencies.\n\nThis study is a pilot research project focusing on the multidimensional assessment of the neurocognitive, psychological, and psychosocial functioning of children between 6 and 8 years old who have received allogeneic hematopoietic stem cell transplantation for primary immunodeficiency for at least 2 years. These stringent criteria aim to limit biases related to the diversity of ages at which care is provided.",[156,157],"Primary Immunodeficiencies","ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION",[159,160,161,162,163],"Primary immunodeficiencies","Allogeneic hematopoietic stem cell transplantation","Neurocognitive functioning","Psychological functioning","Psychosocial functioning","2026-08-13",{"date":115,"type":35},{"date":167,"type":23},"2026-08",{"date":169,"type":23},"2028-08",{"name":41,"class":42},{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":24,"phases":180,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":43},"100648335","ultrasound-assessment-of-joint-health-in-patients-with-mild-hemophilia-factor-levels-5-40-100648335","NCT07719647","Ultrasound Assessment of Joint Health in Patients With Mild Hemophilia (Factor Levels 5-40%)","echoSAHM","Inclusion Criteria:\n\n* Adult (≥18 years old) with congenital mild hemophilia, defined as historical coagulation factor level \\>5% and \\\u003C40% (FVIII or FIX).\n* Affiliated with a social security system.\n* Provided written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patient on prophylactic treatment, defined as at least one of the following:\n\n  o. ≥5 factor concentrate injections per month for a period of more than 6 months o. Treatment with emicizumab o. Last factor concentrate injection within the past 28 days\n* Patient with acquired hemophilia.\n* Patient with uncontrolled chronic rheumatologic disease, such as rheumatoid arthritis, inflammatory spondyloarthropathies, or microcrystalline arthritis.\n* Known pregnancy or breastfeeding.\n* Patient deprived of liberty or under legal guardianship or conservatorship.",{"count":179,"type":23},150,[181],"NA","Currently, few recommendations exist for patients with mild hemophilia, who represent approximately 60% of the hemophilia population. This study aims to provide objective data on joint health in these patients, which are currently limited compared to those with moderate or severe hemophilia.\n\nThe use of joint ultrasound in mild hemophilia could allow early, asymptomatic detection of joint damage, support tailored management including patient education, and ultimately improve quality of life.\n\nThe study will also explore the correlation between coagulation factor levels (FVIII or FIX) and other indicators of joint health in France.",[184],"Mild Hemophilia",[184,186,187,188,189,190,191,192,193],"Hemophilia A","Hemophilia B","Joint Health","Arthropathy","Ultrasound","HEAD-US","Coagulation Factor","Quality of life",{"date":66,"type":35},{"date":196,"type":23},"2027-02",{"date":198,"type":23},"2028-02",{"name":41,"class":42},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":18,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":24,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":43},"100652047","development-of-diffusion-mri-and-tractography-technique-for-the-detection-of-nerve-lesions-in-brachial-plexus-injuries-100652047","NCT07767708","Development of Diffusion MRI and Tractography Technique for the Detection of Nerve Lesions in Brachial Plexus Injuries","Development of Diffusion MRI and Tractography Technique for the Detection of Nerve Lesions in Brachial Plexus Injuries: Feasibility Study","IRM-POPB","Inclusion Criteria:\n\n* Patients aged 14 to 30 years\n* Consulted by the Orthopedics Department at Armand Trousseau Hospital\n* Diagnosed and monitored by Armand Trousseau Hospital for obstetrical brachial plexus palsy (OBBP)\n* Having a single, unoperated lesion (lesions are very different and only exceptionally affect all the roots bilaterally).\n* Not suffering from bone or neurological pathology unrelated to OBP\n* Patients affiliated with or entitled to a social security scheme\n* Patients who have received informed information and have signed, with the investigator, a consent form to participate in the study\n* Parents\u002Flegal guardians who have received informed information and have co-signed, with the investigator, a consent form to participate in the study, for minor patients\n\nExclusion Criteria:\n\n* History of rheumatoid pathologies, constitutional bone diseases, past or current pathologies affecting the arm or neck unrelated to the obstetric brachial plexus, any history of neoplasia or radiographic appearance consistent with a neoplastic fracture\n* Current pregnancy\n* Inability to perform the MRI examination (presence of a contraindication, incapacitating pain, or claustrophobia)\n* Large tattoo present in the area of interest (artifacts)\n* Patients deprived of liberty, or under guardianship\u002Fcuratorship\n* Patients receiving medical assistance (AME)","14 Years","30 Years",{"count":211,"type":23},8,[181],"The objective of this prospective study is to contribute to improving the management of patients with obstetric brachial plexus palsy.\n\nThe main objective is the characterization of the microstructure by diffusion MRI in patients with a history of unoperated obstetrical brachial plexus palsy.",[215],"Obstetric Brachial Plexus Palsy",[217,218,219,220],"obstetric brachial plexus paralysis","magnetic resonance imaging","diffusion tensor imaging","tractography","2026-08-11",{"date":66,"type":35},{"date":224,"type":35},"2026-01-09",{"date":196,"type":23},{"name":41,"class":42},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":239,"conditions":240,"keywords":244,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100651679","eeg-based-decision-support-algorithm-for-hypoxic-ischemic-encephalopathy-in-term-newborns-100651679","NCT07764315","EEG-Based Decision-Support Algorithm for Hypoxic-Ischemic Encephalopathy in Term Newborns","Retrospective Multicenter Validation of a Conventional EEG-Based Decision-Support Algorithm to Discriminate Mild Versus Moderate\u002FSevere Hypoxic-Ischemic Encephalopathy in Term Newborns (Newborn Neuro Digital Project)","COOLDECIDE","Inclusion Criteria:\n\n* No parental opposition to the use of the child's medical data within 1 month of the mailed information notice\n* Gestational age ≥ 36 weeks of amenorrhea\n* Birth weight ≥ 1800 g\n* Born in a context of perinatal asphyxia (any cause) leading to suspected HIE, with EITHER biological signs of metabolic acidosis (pH ≤ 7 or base deficit ≥ 16 mmol\u002FL or lactate ≥ 11 mmol\u002FL within the first hour of life, any blood sample) OR a history of asphyxia with Apgar ≤ 5 at 10 minutes or need for ventilatory resuscitation continued at 10 minutes of life\n* Non-compressed conventional EEG (EEGc) recorded before the 6th hour of life\n* EEG including the signal of active electrodes Fp1, Fp2, T3 and T4\n\nExclusion Criteria:\n\n* Participation in a therapeutic biomedical research liable to modify the EEG tracing\n* Fewer than 20 minutes of artifact-free EEG recording\n* Signal from active electrodes Fp1, Fp2, T3 and T4 not exploitable","0 Days","1 Day",{"count":238,"type":23},310,"This retrospective, multicenter, observational study evaluates how well a decision-support algorithm can tell apart mild forms of hypoxic-ischemic encephalopathy (HIE) from moderate or severe forms in full-term newborns born after a lack of oxygen around birth (perinatal asphyxia). The algorithm reads the raw (non-compressed) EEG signal. Its output is compared with the reference reading of the full conventional EEG made by a panel of pediatric neurophysiologists together with the baby's clinical information. The study uses only medical data that already exists and asks nothing of the babies or their families.",[241,242,243],"Hypoxic-Ischemic Encephalopathy","Perinatal Asphyxia","Neonatal Brain Injury",[245,246,247,248,249,250],"conventional EEG","therapeutic hypothermia","decision-support software","term newborn","diagnostic accuracy","medical device software",{"date":164,"type":35},{"date":253,"type":23},"2026-09-16",{"date":255,"type":23},"2027-02-16",{"name":41,"class":42},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":24,"phases":267,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":278,"leadSponsor":280,"locationsCount":211},"100651561","phase-3-enhancing-amoxicillin-pharmacokinetics-and-pharmacodynamics-parameters-with-probenecid-in-bone-and-joint-infections-100651561","NCT07764302","Enhancing Amoxicillin Pharmacokinetics and Pharmacodynamics Parameters With Probenecid in Bone and Joint Infections","Impact du probénécide Sur Les paramètres pharmacocinétiques et Pharmacodynamiques de l'Amoxicilline Chez Des Patients traités Par Voie Orale Pour Une Infection ostéo-articulaire : étude Quasi-expérimentale Multicentrique Preuve de Concept","AMPHORE","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Effective contraception throughout the study period for women of childbearing potential.\n* Ongoing oral amoxicillin monotherapy for the treatment of a documented osteoarticular infection, including: osteoarticular infection without implanted material (arthritis, osteitis, osteomyelitis), osteoarticular infection involving implanted material (osteoarticular prosthesis, osteosynthesis hardware, external fixator, or arthrodesis material excluding spinal instrumentation), or spondylodiscitis with or without implanted material, defined by the following criteria:\n\n  * Microbiological documentation of one or more pathogens for which amoxicillin is the recommended antibiotic treatment (Enterococcus spp. susceptible to ampicillin, Streptococcus spp., Cutibacterium spp., and other anaerobic bacteria susceptible to amoxicillin), obtained from blood cultures, disco-vertebral biopsy, bone biopsy, joint aspiration, and\u002For intraoperative samples.\n  * Treatment with oral amoxicillin monotherapy for the management of this osteoarticular infection, with the diagnosis established based on the following criteria:\n* Clinical signs, with one or more of the following: fever, hypothermia, chills, pain, spinal pain, arthritis, inflammatory or dehiscent scar over osteoarticular hardware, fistula, purulent drainage, and\u002For\n* Suggestive radiological findings (X-ray, CT scan, or MRI): bone lysis, periosteal reaction, sequestrum, soft tissue collection, joint effusion, radiolucent line around osteoarticular hardware suggestive of loosening. In cases of spondylodiscitis: T2 hyperintensity of the disc, T1 hypointensity of adjacent vertebral endplates on MRI, posterior facet joint arthritis, and\u002For\n* Final diagnosis of osteoarticular infection established by the treating medical or multidisciplinary surgical team based on a combination of clinical, microbiological, radiological, or other relevant findings.\n\nPatients with a history of one or more previous osteoarticular infections are eligible.\n\n* Oral amoxicillin treatment permitted based on clinical and biological improvement.\n* Planned hospitalization duration ≥4 days after inclusion.\n* Patient informed and having provided written informed consent to participate.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Severe allergy to β-lactams or documented allergic contraindication to penicillins confirmed by allergy testing.\n* Contraindication to probenecid, including: hypersensitivity to probenecid, an ongoing acute gout attack, nephrolithiasis, secondary hyperuricemia due to chemotherapy, radiotherapy, or myeloproliferative syndrome because of the increased risk of uric acid nephropathy, and primary hyperuricemia due to uric acid overproduction.\n* Ongoing treatment, which cannot be discontinued, with a medication known to interact with probenecid: methotrexate, diprophylline, cholestyramine, phenobarbital, and zidovudine. If treatment discontinuation is possible, the washout period will be left to the investigator's discretion.\n* Renal impairment defined by an estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m² according to the CKD-EPI equation, based on the most recent value available during hospitalization before inclusion.\n* Augmented renal clearance defined by an eGFR \\>130 mL\u002Fmin\u002F1.73 m² according to the CKD-EPI equation, based on the most recent value available during hospitalization before inclusion.\n* Body weight \\\u003C40 kg or \\>110 kg.\n* Severe hepatic impairment defined by prothrombin time (PT) \\\u003C50%, based on the most recent value available during hospitalization before inclusion.\n* Patients under legal guardianship, curatorship, judicial protection, or deprived of liberty.\n* Patients with cognitive impairment or who, in the investigator's opinion, are unable to understand the study, participate in all study visits considering the treatments and procedures required by the protocol, and\u002For provide informed consent.\n* Patients not affiliated with a social security system or another health insurance scheme, including patients covered by State medical aid (AME).\n* Concomitant participation in another clinical trial involving a medicinal product for human use, a clinical investigation of a medical device, or any interventional research involving human participants.\n* Participation in non-interventional research is permitted",{"count":266,"type":23},57,[26],"Osteoarticular infections (OAIs) are common, with Streptococcus spp. and Enterococcus spp. being the second most common causative pathogens after Staphylococcus aureus. High-dose oral amoxicillin is recommended as first-line treatment for susceptible infections caused by Streptococcus spp., Enterococcus faecalis and anaerobic bacteria. However, treatment failure remains frequent despite appropriate therapy, with reported rates ranging from 25% to 48%.\n\nThe efficacy of β-lactam antibiotics is closely related to PK\u002FPD target attainment, particularly the time during which free drug concentrations remain above the minimum inhibitory concentration (fT \\> MIC). For severe infections such as OAIs, maintaining antibiotic concentrations above the MIC throughout the dosing interval is considered the optimal PK\u002FPD target. Because amoxicillin penetration into bone is limited (bone-to-plasma concentration ratio 0.1-0.3), a trough plasma concentration (Cmin) ≥10 × MIC has been proposed to ensure adequate exposure at the site of infection. Achieving this target is particularly challenging for E. faecalis because of its higher MICs and the saturable oral absorption of amoxicillin at doses ≥2 g. Accordingly, the French Infectious Diseases Society (SPILF) recommends PK\u002FPD-guided dose optimization and therapeutic drug monitoring when oral amoxicillin doses exceed 9 g\u002Fday.\n\nProbenecid inhibits the renal tubular secretion of β-lactams through inhibition of OAT1 and OAT3 transporters, thereby increasing plasma amoxicillin concentrations and prolonging its elimination half-life. This pharmacokinetic interaction has been well documented and may improve PK\u002FPD target attainment without increasing the amoxicillin dose. Current national recommendations advocate high-dose amoxicillin but propose heterogeneous dosing regimens, resulting in substantial variability in prescribing practices. The AMPHORE study aims to generate clinical PK\u002FPD data to establish standardized dosing strategies for oral amoxicillin, with or without adjunctive probenecid.\n\nHypothesis : In patients with osteoarticular infections treated with oral amoxicillin, the addition of probenecid may improve amoxicillin PK\u002FPD target attainment by increasing trough plasma amoxicillin concentrations.\n\nObjective : To evaluate the effect of adding oral probenecid on the trough plasma amoxicillin concentration in patients receiving oral amoxicillin monotherapy for osteoarticular infection.\n\nMethod : Prospective, multicentre, quasi-experimental before-and-after study conducted in eight French hospitals. Fifty-seven patients with microbiologically confirmed osteoarticular infections caused by amoxicillin-susceptible pathogens (Enterococcus spp., Streptococcus spp., Cutibacterium spp. or other amoxicillin-susceptible anaerobic bacteria) receiving oral amoxicillin monotherapy will be included. Following baseline pharmacokinetic sampling, patients will receive oral probenecid (500 mg every 8 hours), with repeat pharmacokinetic assessment.",[270],"Osteoarticular Infections (OAIs)",[272,273,274,275],"Amoxicillin","Probenecid","Osteoarticular infections","Pharmacokinetics\u002Fpharmacodynamics (PK\u002FPD)",{"date":164,"type":35},{"date":142,"type":23},{"date":279,"type":23},"2029-09",{"name":41,"class":42},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":24,"phases":290,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":43},"100562391","phase-2--study-of-the-benefit-of-nebulized-amikacin-in-the-treatment-of-gram-negative-bacillus-pneumonia-acquired-during-mechanical-ventilation-in-patients-receiving-extracorporeal-membrane-veno-arterial-oxygenation--100562391","NCT06602557","\" Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation \"","NAVAP-ECMO","Inclusion Criteria:\n\n1. Patient 18 years or older\n2. Circulatory assistance by veno-arterial ECMO for at least 24 hours prior to documentation of pneumonia\n3. Invasive mechanical ventilation\n4. Diagnostic suspicion of pneumonia based on evocative criteria (presence of at least 2 of the following criteria): fever (superior to 38. 5°C), hypothermia (inferior to 36.0°C), hyperleukocytosis (superior to 11 × 10\\^9 l-1) or leukopenia (inferior to 4 × 10\\^9 l-1), purulent tracheobronchial secretions, altered oxygenation with need to increase FiO2 on ECMO or ventilator for the same SaO2 or PaO2 target, new or persistent pulmonary infiltrate(s) on chest x-ray in bed, or image suggestive of pneumonia on chest CT, or consolidation of appearance suggestive of an infectious origin on pulmonary ultrasound.\n5. And microbiological confirmation of Gram-negative ventilator-associated pneumonia by quantitative culture on bronchoalveolar lavage (BAL, significance threshold superior to 10\\^4 CFU\u002Fml) or protected distal sampling (PDP, significance threshold superior to 10\\^3 CFU\u002Fml).\n6. Probabilistic antibiotic therapy with piperacillin - tazobactam\n7. Informed consent obtained from the patient or trusted support person if unable to consent at the time of inclusion, or inclusion procedure in emergency situations.\n8. Patient affiliated to social security (excluding AME)\n\nExclusion Criteria:\n\n1. Known allergy to amikacin or another aminoglycoside or to an auxiliary drug or to any of their excipients.\n2. Contraindication to the administration of amikacin or its excipients listed in the summary of product characteristics.\n3. Contraindication to the administration of an auxiliary drug or to one of its excipients listed in the summary of product characteristics.\n4. Contraindications to nebulization\n5. Intravenous antibiotic therapy started more than 72 hours before randomization\n6. Probabilistic venous antibiotic therapy other than piperacillin - tazobactam\n7. Administration of inhaled antibiotics within 7 days prior to inclusion\n8. Positive pregnancy test for women of childbearing potential\n9. Presence of HIV infection with CD4 count inferior to 200 cells\u002Fmm3 or fungal lung infection or pulmonary abscess or empyema\n10. Presence of renal insufficiency with creatinine clearance inferior to 15 ml\u002Fmin, with the exception of patients receiving continuous renal purification or daily hemodialysis sessions as part of their intensive care unit management.\n11. Patent moribund (SAPS II superior to 75) or high probability of death within 48 hours\n12. Patient under legal protection (curatorship, guardianship or safeguard of justice)\n13. Participating in another interventional clinical trial or within the exclusion period at the end of a previous study.",{"count":289,"type":23},26,[291],"PHASE2","Pneumonia are the most frequent infectious complication in patients on Extracorporeal Membrane Oxygenation Veno-arterial (ECMO-VA), with a treatment failure rate of around 40%, even though antibiotic therapy is tailored to the germs identified. One hypothesis to explain this particularly high failure rate is the reduced pulmonary blood flow associated with ECMO offloading of the heart. Although there are no data to date on the pulmonary penetration of antibiotics in patients undergoing VA-ECMO, this phenomenon of pulmonary hypoperfusion could contribute to altering the alveolocapillary diffusion of antibiotics, thereby reducing their concentration in the pulmonary parenchyma.\n\nOur hypothesis is that amikacin nebulization could increase bacterial clearance and, ultimately, limit treatment failure or recurrence of gram-negative bacilli (GNB) pneumonia in patients undergoing VA-ECMO.",[294,295],"Pneumonia, Bacterial","Extracorporeal Membrane Oxygenation",[297,298,299,300],"ECMO","Hospital acquired pneumonia","Antibiotic nebulization","Pharmacokinetic",{"date":164,"type":35},{"date":303,"type":35},"2026-08-10",{"date":305,"type":23},"2029-02-10",{"name":41,"class":42},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":43},"100511986","association-between-tinnitus-and-hearing-loss-in-locally-advanced-head-and-neck-cancer-treated-by-radiotherapy-alone-or-with-chemotherapy-a-prospective-and-multicenter-study-100511986","NCT05946577","Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study","Association Between Tinnitus and Hearing Loss in Patients With Locally Advanced Head and Neck Cancer Treated by Concomitant Chemoradiotherapy or Exclusive Radiotherapy: a Prospective and Multicenter Study","AURACCO","Inclusion Criteria:\n\n* Patient with locally advanced or post-operative ENT cancer with high risk of recurrence\n* Patient ≥ 18 years\n* Absence of prior chemotherapy or radiotherapy\n* Patient eligible for chemotherapy with cisplatin according to the standard regimen: radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks associated with chemotherapy with cisplatin 100 mg\u002Fm2 every 3 weeks (i.e. at week 1, 4 and 7)\n* Patient ineligible for cisplatin chemotherapy receiving:\n\n  * Either exclusive radiotherapy (age \\> 70 years, contraindication: renal failure, patient wearing a device): radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks.\n  * either chemoradiotherapy with a chemotherapy protocol different from the standard scheme (due to a contraindication to cisplatin): radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks associated with non-standard chemotherapy ototoxic (cetuximab or carboplatin-5FU)\n\nExclusion Criteria:\n\n* Tinnitus grade ≥ 2 according to the SOMA-LENT scale\n* Patient fitted for hearing disorders\n* Significant cognitive disorders that may compromise the performance of the various assessments\n* Patients treated with weekly cisplatin\n* Patient's refusal to participate in research",{"count":316,"type":23},140,"The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy",[319,320],"Head Cancer","Neck Cancer",[322,323,324,325,326,327,328,329,330,331,332,333,334],"Head and neck cancer","HNSCC","Undifferentiated nasopharyngeal cancer","UCNT","Salivary gland cancer","Radiotherapy","Chemoradiotherapy","Radiochemotherapy","Chemotherapy","Cisplatin","Ototoxicity","Tinnitus","Hearing loss",{"date":164,"type":35},{"date":337,"type":35},"2023-03-09",{"date":339,"type":23},"2029-03-09",{"name":41,"class":42},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":350,"conditions":351,"keywords":356,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":365,"leadSponsor":367,"locationsCount":43},"100651475","kinetics-and-prognostic-value-of-neurofilament-light-in-post-cardiac-arrest-a-prospective-multicenter-study-100651475","NCT07760636","Kinetics and Prognostic Value of NeuroFilament Light in Post-cardiac Arrest: A Prospective Multicenter Study","CINEFIL","Inclusion Criteria:\n\n* Patients admitted to the ICU for cardiac arrest,\n* Patients who regained consciousness following in-hospital or out-of-hospital cardiac arrest,\n* Patients in a coma upon arrival in the ICU, defined by a Glasgow Coma Scale (GCS) score \\\u003C8,\n* Patients included in the AfterROSC2 cohort,\n\nExclusion Criteria:\n\n* Terminally ill patients (death expected within 3 hours of admission to the ICU),\n* Minors,\n* Patients under legal guardianship,\n* Pregnant women,\n* Patients not enrolled in a social security program,\n* Prior inclusion in the CINEFIL study,\n* Restriction of active therapies prior to the first NFL biomarker assay,\n* Objection by a family member or trusted person, if present",{"count":349,"type":23},270,"The purpose of this study is to assess the prognostic value of absolute value and kinetic of neurofilament light chain (NFL) collected at different time points (at admission, 12h, 24h, 48h, 72h, 96h, and day 7 after ICU admission) in predicting poor and good neurological outcome in comatose patients after cardiac arrest.",[352,353,354,355],"Cardiac Arrest (CA)","Intensive Care Unit (ICU) Admission","Return of Spontaneous Circulation","Comatose",[357,358,359,360,361],"Cardiac arrest","Coma","Neuroprognostication","Biomarkers","Neurofilament light chain",{"date":363,"type":35},"2026-08-12",{"date":94,"type":23},{"date":366,"type":23},"2028-06",{"name":41,"class":42},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":106,"sex":18,"minAge":19,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":24,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":43},"100628515","signature-response-to-light-therapy-in-unipolar-and-bipolar-major-depressive-episode-mde-100628515","NCT07462637","Signature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE)","SoLuRep","Patients :\n\nInclusion Criteria:\n\n1. Adults between 18 and 65 years old\n2. Patients with a diagnosis of MDE as part of a unipolar or bipolar disorder (DSM-5 TR criteria)\n3. Patients with a clinician-rated MADRS score ≥ 20 indicating a moderate to severe depressive symptoms with a prescription of LT for MDE treatment\n4. For patients with bipolar disorder type 1: With prophylactic mood stabilizer treatment at an effective dose (standardized and at a preventive dose for manic episode prevention) and stable for at least 4 weeks (background treatment for bipolar disorder): Lithium (Téralithe® LP 400 or 250) or Sodium Valproate (Dépakote® 500) or Atypical antipsychotics (also known as second-generation antipsychotics), defined as follows and dosed prior to inclusion in the month preceding:\n\n   * For Lithium, controlled by serum lithium level, \\>0.5 mEq\u002FL for Téralithe 250 and \\> 0.7 mEq\u002FL for Téralithe LP 400 ; for Sodium Valproate, controlled by serum sodium divalproate level \\>40mg\u002FL\n   * For antipsychotics, only the following molecules will be accepted at the indicated dosages, as they have marketing authorization in France as prophylactic mood stabilizers for manic episode prevention in bipolar disorder: Quétiapine (≥150-800mg), Aripiprazole (≥ 15-30mg), Olanzapine (≥ 10-20mg)\n5. Patients for whom light therapy is prescribed\n6. Patients able to understand French.\n7. Patients able to sign informed consent.\n\nExclusion Criteria:\n\n1. Patients with a DSM-5 diagnosis of schizophrenia, suffering from paranoid or delusional disorders, any other psychotic features or other nonstabilized mental disorders\n2. Patients with other antidepressant strategies than LT or mood stabiliser initiated in the month prior to inclusion\n3. Patients with a therapeutic resistance of current MDE (lack of response to ≥2 antidepressants of 2 different classes at therapeutic doses for \\>6 weeks)\n4. Patients with a LT used in the last 1 month\n5. Patient with ophtalmic pathologies (cataract, glaucoma, age-related macular degeneration, severe myopia \\> 6D, etc.) or diseases affecting the retina (retinitis pigmentosa, diabetes, herpes, hereditary retinal disorders etc.).\n6. Patient with photosensitive epilepsy\n7. Patients with a C-SSRS score ≥ 4\n8. For the MRI group, patient presenting one or several MRI contrindications\n9. Shiftwork or self-imposed irregular sleep schedule within the last months\n10. Travel acrosss 2 time-zones during the last month prior to participation\n11. Pregnant or breastfeeding women\n12. Subject under guardianship or deprived of liberty\n13. Participation ton another interventional study\n\nHealthy volonteers :\n\nInclusion criteria :\n\n1. Adults between 18 and 65\n2. Without any significant psychiatric history or current psychotropic medication\n3. Able to understand French\n4. Able to sign informed consent\n\nExclusion criteria :\n\n1. Contra-indications to MRI (claustrophobia, metallic or material implants)\n2. History of severe head injury\n3. Pregnancy and breastfeeding woman\n4. Inability to understand information about the study\n5. Persons deprived of their liberty by judicial or administrative decision\n6. Adult subject under legal protection or unable to consent","65 Years",{"count":377,"type":23},173,[181],"Major depressive episode (MDE) are severe and common psychiatric disorders that affect up to 20% of the general population. MDE cause a decrease in psychosocial functioning, quality of life, and is associated with a high rate of suicides. They will be the leading cause of disability by 2030 according to the World Health Organization. The international effort carried out to identify biomarkers of MDE has been hampered by the heterogenous nature of MDE (unipolar, bipolar, seasonal, non-seasonal) and their heterogeneous response to treatment. Response rate to antidepressant drugs is only 40 to 50%, leading to the use of drug combinations and development of alternative therapeutics such as light therapy (LT). It was demonstrated that LT, as a first line treatment of MDE with and without seasonal pattern (± SP), has comparable efficacy to antidepressants. LT has the advantage of being also effective in improving both sleep, alertness and circadian rhythms, which may be altered in depression, contrary to antidepressant drugs that target mainly mood. Further research is warranted to determine the most efficient lighting parameters to use depending on depression characteristics, as well as to identify signature biomarkers of response. Besides, no studies have directly evaluated both subjective and objective biomarkers of sleep, wake, biological rhythms, and light signalling pathways and activation in patients with MDE ± SP. The main objective of the research will be to identify the signature of response to LT examining the correlation between the measures of biological and clinical parameters before LT and their evolution at the end of the procedure, and the therapeutic response.\n\nThe primary endpoint of the study will be the therapeutic response to LT measured by the difference of MADRS score between Visit 1 and Visit 4 (end of the therapeutic protocol). Therapeutic response to LT considered as a success will be defined as at least a 50% reduction of MADRS score between the two visits.",[381],"Major Depressive Episode",[383,384,385],"major depressive episode","light therapy","seasonal pattern",{"date":363,"type":35},{"date":388,"type":35},"2026-06-17",{"date":390,"type":23},"2029-08",{"name":41,"class":42},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":375,"enrollmentInfo":400,"targetDuration":4,"studyType":24,"phases":402,"briefSummary":403,"conditions":404,"keywords":406,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":43},"100602236","phase-3-efficacy-of-chronotherapeutic-combination-for-major-depressive-episode-with-insomnia-100602236","NCT07120880","Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","Efficacy of a Combination of Chronotherapeutics for the Treatment of Major Depressive Episode (MDE) With Insomnia: a Multicenter, Randomized, 2*2 Factorial, Double-blind, Placebo-controlled Trial","CombiChronoS","Inclusion Criteria:\n\n1. Adults aged between 18 and 65 years (to avoid the risk of cataract associated with light therapy) with a diagnosis of a major depressive episode (MDE) in the context of unipolar depression (according to DSM-5 criteria).\n2. Diagnosis of comorbid insomnia with the MDE, defined by difficulty initiating sleep, and\u002For maintaining sleep, and\u002For early morning awakenings with daytime consequences, occurring at least three times per week (according to DSM-5 and ICSD-3, in line with European guideline recommendations).\n3. Outpatients or inpatients treated for MDE in one of the psychiatric departments of the study centers, or in the sleep medicine department, for a minimum treatment duration of 8 weeks.\n4. Patients not currently receiving antidepressant treatment for the current MDE (previous use of antidepressants is allowed, provided treatment was stopped at least one month prior to study participation).\n5. A MADRS score ≥ 20 (clinician-rated), indicating at least a moderate-intensity depressive episode.\n6. An ISI score ≥ 8 (clinician-rated), indicating at least mild and clinically significant insomnia.\n7. No exposure to light therapy in the month prior to inclusion.\n8. Ability to understand and sign the informed consent form.\n9. Use of highly effective contraception for women of childbearing potential.\n\nExclusion Criteria:\n\n1. Individuals under legal guardianship or deprived of liberty\n2. Ophthalmologic conditions (e.g., cataract, glaucoma, age-related macular degeneration) or diseases affecting the retina (e.g., retinitis pigmentosa, diabetes, herpes, etc.)\n3. The following disorders (according to DSM-5): schizophrenia and other psychotic disorders; bipolar disorder, particularly (hypo)manic episodes (YMRS score ≥ 12); other unstable mental disorders\n4. Other unstable general medical conditions\n5. Pregnant or breastfeeding women\n6. Hypersomnia with prolonged total sleep time secondary to the depressive episode, according to ICSD-3 criteria\n7. Current depressive episode already being treated with an antidepressant\n8. Presence of a high suicidal risk, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS, score ≥ 4)\n9. Ongoing melatonin treatment at the time of inclusion",{"count":401,"type":23},184,[26],"Major Depressive Disorder (MDD) affects 5% of the global population and is the second leading cause of disability worldwide. Despite the widespread use of antidepressants, 50-60% of patients do not respond adequately after 8 weeks of treatment. Insomnia, present in approximately 85% of individuals with MDD, is a frequent and persistent symptom that contributes to poor treatment outcomes. Targeting insomnia has been shown to enhance both symptom remission and functional recovery. In this context, combined therapeutic strategies are often used to optimize the antidepressant response. Among them, chronotherapeutic approaches, such as light therapy and prolonged-release melatonin, have demonstrated rapid antidepressant effects and are beneficial in regulating sleep and circadian rhythms. Light therapy shows an efficacy comparable to antidepressants and, when used in combination with them, can double treatment effectiveness. Melatonin is also recommended in the management of depression-related insomnia. This multicenter, randomized, double-blind, placebo-controlled trial with a 2x2 factorial design aims to evaluate the efficacy of two chronotherapeutic interventions, 8 weeks of active light therapy and 2 mg of prolonged-release melatonin-administered alone or in combination, on depressive symptom reduction at 8 weeks in adult patients with MDD and comorbid insomnia. The primary outcome is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to week 8. All participants will receive antidepressant treatment and sleep hygiene education. This study proposes a novel therapeutic strategy combining pharmacological and non-pharmacological interventions to address both depression and insomnia, with the goal of improving outcomes, especially for the 40% of patients who do not adequately respond to antidepressants alone.",[405],"Major Depressive Disorder (MDD) With Insomnia",[407,408,409,410],"Major depressive episode","Insomnia","Light therapy","Melatonin",{"date":363,"type":35},{"date":413,"type":35},"2026-01-28",{"date":415,"type":23},"2029-01",{"name":41,"class":42},{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":426,"conditions":427,"keywords":428,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":43},"100505869","cohort-of-patients-suffering-from-major-depressive-episode-with-evaluation-of-sleep-circadian-rhythms-and-psychiatric-disorders-100505869","NCT05866991","Cohort of Patients Suffering From Major Depressive Episode With Evaluation of Sleep, Circadian Rhythms and Psychiatric Disorders","SoPsy-SoSad","Inclusion Criteria:\n\n* Individuals with depressive episode characterized according to the DSM-5 criteria regardless of the associated characteristics and comorbidities.\n* Adult and child\n* Affiliated to a social security\n\nExclusion Criteria:\n\n* don't understand or read french\n* Medical condition incompatible with administration of questionnaire\n* impossibility to give informed decision (subject in an emergency condition, etc.)",{"count":425,"type":23},1000,"Despite international efforts to identify biomarkers of depression, none has been transferred to clinical practice, neither for diagnosis, evolution, nor therapeutic response. This led us to build a French national cohort (through the clinical and research network named SoPsy within the French biological psychiatry society (AFPBN) and sleep society (SFRMS)), to better identify markers of sleep and biological rhythms and validate more homogeneous subgroups of patients, but also to specify the manifestations and pathogeneses of depressive disorders.",[381],[429,360,430,431,432,433,434],"Depression","Depressive","Disorder","Sleep","circadian rhythms","seasonal affective disorder",{"date":363,"type":35},{"date":437,"type":35},"2023-02-01",{"date":439,"type":23},"2033-05-01",{"name":41,"class":42},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":24,"phases":451,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":466,"locationsCount":43},"100455503","phase-2-rituximab-in-patients-with-st-elevation-myocardial-infarction-100455503","NCT05211401","Rituximab in Patients With ST-elevation Myocardial Infarction","Rituximab in Patients With ST-elevation Myocardial Infarction: A Phase 2 Placebo-controlled Randomized Clinical Trial: RITA-MI 2","RITA-MI2","Inclusion Criteria:\n\n* Age ≥ 18 years with no upper limit (women must be either postmenopausal defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile, e.g. age appropriate (\\>55 years old), history of vasomotor symptoms) or having documented hysterectomy and\u002For bilateral oophorectomy) ;\n* \\- Clinical evidence at presentation of anterior ST-elevation myocardial infarction (STEMI) defined as symptoms suggestive of acute myocardial ischemia, an electrocardiogram showing ST-segment elevation ≥2 mm in ≥2 contiguous leads in V1 to V4 or a large inferior MI with evidence of low-ejection fraction (LVEF\\\u003C45%);\n* Complete occlusion (i.e. TIMI flow 0-1) of proximal or mid left anterior descending (LAD) coronary artery on urgent angiography interpreted as the infarct-related artery (IRA);\n* Onset of worse symptoms within 48 hours before primary PCI;\n* Patients with neutrophils \\>1.5 x 109\u002FL at the moment of admission\n* Patients with platelet counts \\>75 x 109 \u002FL at the moment of admission\n* Plan to provide primary percutaneous angioplasty (PPCI) for the patient within 2 hours of ECG diagnosis; confirmed before enrollment;\n* Ability to start infusion of rituximab within 3 hours of PPCI ; confirmed before enrollment;\n* Written informed consent.\n\nExclusion Criteria:\n\nExclusion Criteria :\n\n* History of previous MI without documented preserved left ventricular ejection fraction (LVEF \\>50%) prior to the current admission will be an exclusion criterion;\n* Presentation with cardiac arrest;\n* Cardiogenic shock (defined as systolic blood pressure \\\u003C90 mmHg for \\>30minutes, or necessitating vasopressors to achieve a blood pressure ≥90 mmHg);\n* Cardiac electrical instability (defined as complete heart block needing temporary pacing or any tachyarrhythmia needing cardioversion);\n* Patients with Killip class III heart failure;\n* History of severe chronic renal failure (define as stage 4 (GFR = 15-29 mL\u002Fmin) or worse);\n* History of hepatitis B, HIV or tuberculosis;\n* Patient positive for point of care bedside test of Ag HBs;\n* Severe, progressive infections documented;\n* Active COVID-19 infection or COVID-19 infection within 3 months;\n* Patient with documented severe immune deficiency;\n* Presence, or history in ≤ five years, of an ongoing cancer, (except in situ cancer of the cervix or basal cell carcinoma);\n* QTcF\\> 450 msecs in males, \\> 470msecs in females;\n* Any oral or intravenous immunosuppressive treatment, immune modulatory monoclonal antibodies or immunodepleting therapy at any time (inhalers and topical creams with corticosteroids are permitted);\n* Previous history of major organ transplant including renal transplant;\n* Known hypersensitivity to the active substance of rituximab or to proteins of murine origin, or to any of the other excipients;\n* Any contraindications to any of the rituximab premedication drugs;\n* Contraindications to injectable Polaramine:\n\nRisk of closed-angle glaucoma, Risk of urinary retention linked to urethro-prostatic disorders;\n\n* Expected need for vaccination with a live attenuated vaccine during the study, including incomplete vaccination courses (in case, life, attenuated vaccine must be administered at least 30 days before inclusion in study);\n* Absence of a complete COVID-19 vaccination scheme (including recovery from documented COVID infection) as approved at the time of enrollment in the country where the patient is recruited;\n* Any obvious contraindications for MRI or conditions which will impede image acquisition for example:\n\nSevere claustrophobia\n\nNon-MRI compatible permanent pacemaker\n\nPatients who have a metallic foreign body (metal silver) in their eye, or who have an aneurysm clip in their brain\n\nPatients who have had metallic devices placed in their back\n\nKnown hypersensitivity to imaging products (gadoteric acid, meglumin or any drug containing gadolinium)\n\n* Known hepatic failure;\n* Previous history of progressive multifocal leukoencephalopathy;\n* Inclusion in other interventional drug study within the previous 3 months;\n* Inability to comply with study procedures;\n* Patients under guardianship or curatorship.",{"count":450,"type":23},372,[291],"The main objective is to compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left ventricular systolic function, using CMR, in patients who have had an acute anterior STEMI. Following the sponsor's decision to stop enrolment in the 200 mg arm, the primary objective of the study is to evaluate the efficacy of a single 1000 mg dose of rituximab versus placebo.\n\nThe primary endpoint is the left ventricular ejection fraction (LVEF) by CMR at 6 months.",[454],"ST Elevated Myocardial Infarction",[456,457,458,459,460,461],"Acute Myocardial Infarction","Anterior STEMI","Rituximab","Left ventricular systolic function","CMR","Cardiac remodelling",{"date":363,"type":35},{"date":464,"type":35},"2022-06-01",{"date":71,"type":23},{"name":41,"class":42},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":475,"enrollmentInfo":476,"targetDuration":4,"studyType":24,"phases":478,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":495},"100416793","phase-1-study-evaluating-the-safety-and-the-efficacy-of-human-t-lymphoid-progenitor-htlp-injection-to-accelerate-immune-reconstitution-after-umbilical-cord-blood-ucb-transplantation-in-adult-patients-with-hematologic-malignancies-htlp-onco-100416793","NCT04707300","Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)","A Phase I\u002FII Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies","HTLP-ONCO","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old and \\\u003C66 years old) at the time of inclusion and eligible for an allogeneic stem cells transplantation and fit to receive the specified conditioning regimen\n* Patients with hematologic malignancies\n* Absence of a matched - related sibling donor (MSD) or a matched unrelated donor (MUD) 10\u002F10\n* Presence of two UCB units with the following criteria\\*: HLA- matched 4\u002F8, 5\u002F8, 6\u002F8, 7\u002F8 or 8\u002F8 for HLA- A, -B, -C and DRB1 loci\n\nAND\n\n• Presence of at least one UCB unit with the following criteria\\*: ≥ 3 x 10e7 TNC\u002Fkg or ≥ 1.5 10e5 CD34+\u002Fkg pre- freezing\n\n\\* For the UCB taken into HTLP culture, the CD34+ content does not need to meet the above cellularity criteria, as expansion during HTLP culture has been proven to ensure the appropriate number of CD7+ needed for each dose.\n\nThe non- cultured UCB will be chosen to have a higher CD34+ cell content in order to enable long- term hematopoietic engraftment\n\n* Absence of Donor Specific Antibodies (DSA) with a MFI \\> 5000\n* Patient affiliated to social security\n* Written, informed consent of the patient\n\nExclusion Criteria:\n\n* Any of the standard contraindications to allogeneic transplant\n* Left ventricular ejection fraction \\\u003C50%\n* Abnormal biochemistry results (ALT\u002FAST\\>10xULN, total bilirubin\\>2.5xULN, creatinin clearance \\\u003C60ml\u002Fmin)\n* Inability to understand and provide informed consent\n* Concomitant infectious disease: HTLV-I, HIV-I or HIV-II\n* Pregnancy or breastfeeding for women of childbearing potential\n* Patients with progressive hematologic malignancies\n* Previous participation within one month before inclusion in another protocol in which drugs may influence immune reconstitution of bone marrow transplantation","66 Years",{"count":477,"type":23},10,[479,291],"PHASE1","This is an open-labelled and non-controlled Phase I\u002FII clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.",[482],"Hematologic Malignancy",[484,485,486,487,488],"acute myeloid leukemia","minimal residual disease","hematologic malignancies","human T Lymphoid Progenitor","umbilical cord blood transplantation",{"date":363,"type":35},{"date":491,"type":35},"2022-02-16",{"date":493,"type":23},"2029-02",{"name":41,"class":42},5,{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":503,"minAge":19,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":24,"phases":507,"briefSummary":508,"conditions":509,"keywords":513,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":43},"100624622","identification-of-women-with-severe-insulin-resistant-syndromes-of-genetic-origin-among-patients-with-classic-polycystic-ovary-syndrome-pcos-100624622","NCT07412028","Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With \"Classic\" Polycystic Ovary Syndrome (PCOS)","ANDROLIPO","Inclusion Criteria:\n\n* Women aged ≥ 18 years and \\\u003C 45 years ;\n* Discontinuation of estrogen-progestin therapyfor at least 3 months ;\n* Signed informed consent ;\n* Social security affiliation.\n\nCase (n=25):\n\n\\- Patient with a lipodystrophic syndrome due to a known pathogenic variant of the LMNA gene.\n\nControl (n=50), :\n\n\\- patient consulting for polycystic ovary syndrome (PCOS according to the Rotterdam criteria) in day hospital matched on age +\u002F-5 years and BMI+\u002F-5 kg\u002Fm2.\n\nExclusion Criteria:\n\n* \\- Severe renal insufficiency (GFR \\\u003C 30 ml\u002Fmin) ;\n* Hepato-cellular insufficiency (TP \\\u003C 50%) ;\n* Taking corticosteroids or antiretrovirals ;\n* Menopausal women ;\n* Taking estrogen-progestin therapy;\n* Diabetic patients on insulin : type 1 diabetes or pancreatectomised patients\n* Other known causes of hyperandrogenism (21-hydroxylase block, Cushing's syndrome, ovarian tumor).\n* Pregnant woman\n* Breastfeeding woman","FEMALE","45 Years",{"count":506,"type":23},81,[181],"Diagnostic case-control study (1 case for 2 controls). Inclusion of patients with severe insulin resistance syndrome of genetic origin, then inclusion of controls: patients examined for PCOS in day hospital with matching age (+\u002F- 5 years) and Body mass index (+\u002F- 5kg\u002Fm2).",[510,511,512],"Polycystic Ovary Syndrome","Familial Partial Lipodystrophy","LMNA (LaMin Nuclear A) Related Disorders",[510,511,514],"LMNA related disorders","2026-08-07",{"date":303,"type":35},{"date":518,"type":35},"2026-07-21",{"date":520,"type":23},"2028-01",{"name":41,"class":42},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":532,"conditions":533,"keywords":549,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":4},"100649638","inflammatory-disease-biobank-for-immunophenotyping-and-cardiovascular-research-100649638","NCT07737470","Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research","INFLAMMATORY AND IMMUNE-MEDIATED DISEASES BIOBANKING FOR IMMUNOPHENOTYPING AND CARDIOVASCULAR RESEARCH","INFLAME-BANK","Inclusion Criteria:\n\n* Patient enrolled in EACVI-INFLAME study\n* The patient consents\n\nExclusion Criteria:\n\n* Patients with a history of heart transplant\n* Patient unable to provide informed consent\n* Patient under complete or limited guardianship\n* Patient affected by pre-existing immunodeficiency, including HIV (not including immunosuppressive treatment)",{"count":531,"type":23},300,"INFLAME-BANK is a French multicenter prospective observational ancillary study of the international EACVI-INFLAME project. It aims to establish a biobank and perform immunophenotyping and proteomic analyses in patients with suspected inflammatory cardiovascular diseases and autoimmune rheumatic diseases (ICARDs).\n\nThe primary objective is to identify immune biomarkers associated with cardiovascular prognosis and develop disease-specific prognostic scores to predict 1-year major adverse cardiovascular events (MACE). Secondary objectives include evaluating the diagnostic and prognostic value of immunoproteomic biomarkers, assessing the role of photon-counting CT (PCCT) imaging, and investigating immune signatures associated with genetic variants in acute myocarditis.\n\nThe study plans to enroll 300 patients from French centers participating in EACVI-INFLAME. Blood samples will be collected during routine clinical care at inclusion, with optional follow-up sampling at 12 months and optional PCCT imaging and genetic analyses depending on each center's participation. Patients will be followed for 12 months to monitor cardiovascular outcomes.\n\nThe expected impact is to improve understanding of the immune mechanisms underlying ICARDs, facilitate earlier diagnosis and risk stratification, identify new therapeutic targets, and ultimately support more personalized management of patients with inflammatory cardiovascular diseases.",[534,535,536,537,538,539,540,541,542,543,544,545,546,547,548],"Pericarditis","Tako-TSUBO Cardiomyopathy","Myocarditis","Inflammatory Cardiomyopathies","Lupus","Systemic Sclerosis","Antiphospholipid Syndrome","Idiopathic Inflammatory Myopathies","Rheumatoid Arthritis","Spondyloarthritis","ANCA-associated Vasculitis","Takayasu Arteritis","Giant Cell Arteritis","Behçet Disease","Still Disease",[550,551,552,553,554,360,555,556,557,558],"Inflammatory cardiovascular diseases (ICARDs)","Autoimmune rheumatic diseases","Cardiovascular involvement","Immunophenotyping","roteomics","Biobanking","Major adverse cardiovascular events (MACE)","Cardiovascular imaging","Prospective observational study","2026-08-06",{"date":303,"type":35},{"date":562,"type":23},"2026-09-01",{"date":564,"type":23},"2028-10-01",{"name":41,"class":42},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":574,"enrollmentInfo":575,"targetDuration":4,"studyType":24,"phases":577,"briefSummary":578,"conditions":579,"keywords":582,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":43},"100636884","therapeutic-approach-of-repeated-transient-blood-brain-barrier-opening-in-amyotrophic-lateral-sclerosis-100636884","NCT07571486","Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis.","Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis. A One-arm, Single-center, Proof-of-concept Study (Son-ALS)","Son-ALS","Inclusion Criteria:\n\n1. Age 18-80 years,\n2. Able and willing to give signed and informed consent\n3. Confirmed diagnosis of ALS using the Gold Coast criteria with involvement of both upper and lower motor neurons in at least one body region, i.e. patients classified as \"definite\", \"probable\", \"probable laboratory supported\" or \"possible\" ALS using the El Escorial categories (patients with only lower motor neuron involvement will not be included)\n4. Disease duration \\\u003C= 36 months,\n5. Mild functional impairment (ALSFRS-R ≥30),\n6. Change in ALSFRS-R score between 0.35 points and 1.1 points per month (both inclusive) in the period from onset of first symptoms to the Screening visit,\n7. Slow Vital capacity \\>= 70% of normal,\n8. If taking riluzole, patient on stable dose for over 30 days prior to study entry,\n9. Able and willing to follow trial procedures including site travels and visit requirements\n\nExclusion Criteria:\n\n1. Patients with an uncontrolled intercurrent illness or any pre-existing comorbidities that in the Investigator's opinion may prevent the implantation of the device or may impair the ability of the patient to receive treatment with SonoCloud or may be cofounding for evaluation of the clinical trial\n2. Cardiac pacemaker (contraindication to MRI)\n3. Allergy to any drug used in the study (Gadolinium, Xylocain, Cloxacilline, EMLA, echographic contrast agent microbubbles: SonoVue®)\n4. Severe or instable chronic or acute disease or any life-threatening condition\n5. Other significant neurological or psychiatric disease in addition to ALS, including history of uncontrolled seizures\n6. Treatment with edaravone, tofersen or with another investigational drug or biological agent within 1 month or 5 half-lives of study agent, whichever is longer, before screening\n7. Invasive or non-invasive mechanical ventilation use\n8. Gastrostomy or nasogastric tube use\n9. Known right-to-left shunts,\n10. Known severe pulmonary hypertension (pulmonary artery pressure \\>90 mmHg), uncontrolled systemic hypertension\n11. Known respiratory distress syndrome\n12. Women of child-bearing potential or sexually active man, without contraception\n13. Pregnant or breast-feeding woman\n14. History or positive test result at screening for HIV, current hepatitis C infection (defined as positive HCV antibody and detectable HCV RNA) or current hepatitis B infection (defined as positive for HBsAg and\u002For total anti-HBc). Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study. Participants with immunity to hepatitis B from previous natural infection (defined as negative HbsAg, positive anti-HBc, and positive anti-HBs) or vaccination (defined as negative HbsAg, negative anti-HBc, and positive anti-HBs) are eligible to participate in the study.\n15. Patient not affiliated or beneficiary of a social security category","80 Years",{"count":576,"type":23},23,[479,291],"This is proof-of-concept, single-arm, single-center study to assess the safety and explore the efficacy of repeated US transient disruptions of the blood-brain barrier (BBB) in Amyotrophic Lateral Sclerosis (ALS).\n\nPhase 1:\n\nThe primary objective is to assess the safety of ultrasound induced BBB opening in the upper motor neuron area and adjacent supplementary motor area in adult patients with ALS, as assessed by adverse events frequency and severity during study (incidence of AE summarized by system organ class and\u002For preferred term and severity) based on the Common Terminology Criteria for Adverse Events, version 5.0 A run-in period of 12 weeks between inclusion and baseline will take place for each patient in order to evaluate precisely disease progression rate, disease severity and to collect concomitant medication. After this run-in period, the patient will be implanted with the SC4 device (baseline visit). The first sonication session will be performed two weeks after implantation. A total of 9 sonications, with no concomitant drug administration, will be performed over a period of 24 weeks.\n\nPhase 2a:\n\nBased on the safety outcome of the Phase 1, an expansion cohort will open to assess the first signal of efficacy of the US transient disruptions of the BBB in ALS. The primary objective will be to assess the first signal of efficacy of the procedure on disease progression over 26 weeks evaluated by the change from baseline to week 26 of neurofilament light (NfL) levels in blood.The Phase 2a will continuously include 11 additional patients. Patients will be treated according to the same schedule as in phase 1",[580,581],"Amyotrophic Lateral Sclerosis","Charcot Disease",[583,584,585,586,587],"Neuroinflammation","Motor neuron","Blood-brain barrier","Ultrasounds","Innovative medical device",{"date":303,"type":35},{"date":590,"type":35},"2026-07-15",{"date":592,"type":23},"2031-07-15",{"name":41,"class":42},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":602,"conditions":603,"keywords":606,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":612,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":43},"100629054","health-economic-evaluation-of-non-invasive-prenatal-exclusion-diagnosis-100629054","NCT07469657","Health Economic Evaluation of Non-Invasive Prenatal Exclusion Diagnosis","PRENATSAFE","Inclusion Criteria:\n\n* Couple aged over 18 years\n* Ongoing pregnancy of at least 7 weeks gestational age\n* Requesting, within clinical care, invasive prenatal diagnosis or PCR-based NIPD for a particularly severe monogenic disorder, with indication confirmed by a Multidisciplinary Prenatal Diagnosis Center (CPDPN)\n* Eligible for exclusion diagnosis\n* Causative gene covered by the Agilent V8 exome capture kit\n* Affiliated with the national general social security system\n* Informed consent obtained from the pregnant woman and her partner\n\nExclusion Criteria:\n\n* Prenatal diagnosis request not approved by a Multidisciplinary Prenatal Diagnosis Center (CPDPN)\n* Disorder not analyzable by next-generation sequencing (e.g., triplet repeat expansions, sequence homology)\n* Woman carrying the pathogenic variant\n* Woman or partner deprived of liberty, under guardianship or curatorship\n* Index case other than the father, a child, or a fetus from a previous pregnancy within the couple.",{"count":531,"type":23},"Since the discovery of a small fraction of circulating cell-free fetal DNA (ccffDNA) in the blood of the mother, non-invasive prenatal diagnosis (NIPD) techniques using a simple blood sample have been developed to 1) screen for chromosomal abnormalities, 2) diagnose fetal sex, and 3) detect variants not carried by the mother (exclusion NIPD by PCR).\n\nExclusion NIPD by PCR is currently available for certain common variants, but developing it for each variant takes 3-6 weeks per center. The development process for PCR NIPD is lengthy and costly for each variant tested, thereby restricting access to this technique. In practice, this technique is not widely available to couples at risk of transmitting a severe monogenic disease in France, due to the large number of different genes and multiple variants of a given gene.\n\nNext-generation sequencing (NGS) is based on the simultaneous, parallel execution of millions of sequencing reactions, enabling the same nucleotide sequence to be sequenced hundreds of times. It provides qualitative information on the nature of the sequenced base, as well as quantitative information on the number of times the base has been sequenced (reads). Although it only allows for the analysis of around 2% of the entire genome, NGS sequencing of the exome corresponds to almost all the exons of the 22,000 or so genes in our genome. However, this generates a large amount of data, leading to additional costs.\n\nSince its widespread adoption by diagnostic laboratories, some teams have developed an NGS-based NIPD for the exclusion of a pathogenic variant. It allows the analysis of multiple pathogenic variants without requiring an additional development phase. They have demonstrated that NGS-based NIPD is a robust and reliable technology, but one that incurs additional reagent costs.\n\nIn France, 1,700 to 1,800 prenatal diagnostic tests (PND) for monogenic diseases are performed each year due to family history. Between 35 and 40% of couples undergoing invasive PND could benefit from NIPD by NGS, as proposed in the PrenatSafe project. The increased availability of NIPD, whether by PCR or NGS, could also affect couples' demand in the long term. In France, the introduction of NIPD by NGS is likely to lead to an increase in requests for NIPD, as many couples with a low risk of recurrence (in the case of de novo mutations) will probably opt for it due to its lack of iatrogenicity.\n\nThe rapid and widespread rise of NIPD by NGS, made possible by the use of a standardized, generalizable technique such as NGS, will transform our practices throughout the country. The PrenatSafe project therefore aims to evaluate the cost\u002Fbenefit ratio of NIPD by NGS compared to the current standard procedure: NIPD by PCR when performed in clinical practice or PND by invasive sampling (trophoblast biopsy or amniocentesis), using an automated, standardized NGS technique involving exome sequencing, which covers almost all indications for exclusion NIPD.\n\nThis project is the first cost-consequence analysis of prospective exome-based NIPD, using a single standardized technique. The aim is to translate this innovative technology into routine practice if it proves beneficial and economically viable. Exome-based NIPD for exclusion can be fully automated, from ccfDNA extraction to sequencing. This reduces the risk of human error and brings turnaround times in line with the requirements of prenatal diagnosis. If successful, exome-based NIPD would become an earlier alternative to invasive PND without increasing the risk of fetal loss. It would be available for a very large number of indications and could easily be transferred to other prenatal diagnosis centers in France.",[604,605],"Monogenic Diseases","Genetic Diseases, Inborn",[607,608,609,610,611],"Prenatal Diagnosis (PND)","Non-Invasive Prenatal Diagnosis (NIPD)","Circulating Cell-Free Fetal DNA (cffDNA)","Next Generation Sequencing (NGS)","Cost and Outcomes",{"date":303,"type":35},{"date":614,"type":35},"2026-03-26",{"date":616,"type":23},"2029-05",{"name":41,"class":42},{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":627,"conditions":628,"keywords":630,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":635,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":639,"locationsCount":43},"100628556","translation-and-cross-cultural-adaptation-into-french-of-the-comfortneo-pain-assessment-tool-for-newborns-100628556","NCT07463170","Translation and Cross-Cultural Adaptation Into French of the COMFORTneo Pain Assessment Tool for Newborns","TradNeo","Inclusion Criteria:\n\n* Licensed healthcare professionals currently working in a neonatal care unit.\n* Healthcare professionals authorized by their professional qualifications or regulations to assess patient pain, including nurses, specialized nurses, and physicians.\n* Healthcare professionals employed at AP-HP (Assistance Publique - Hôpitaux de Paris).\n\nExclusion Criteria:\n\n\\- Refusal to participate, indicated by non-response to the questionnaire.",{"count":626,"type":23},50,"Observational pain assessment scales are essential for the management of pain in young children, particularly in newborns.\n\nNumerous observational pain assessment scales for newborns and preterm infants exist worldwide; however, only four are available in validated French versions: EVENDOL, EDIN, DAN, and Comfort-B, each with specific indications for use. These scales were developed in France, validated in French, or recommended by expert groups (Comfort-B).\n\nThe COMFORTneo scale was developed and validated by a Dutch research team for the assessment of pain in term and preterm newborns, regardless of their level of ventilation or sedo-analgesia. Although it has been validated in several languages, no validated French translation is currently available.",[629],"Pain",[629,631,632,633,634],"Newborns","Pain Assessment Scales","COMFORTNeo","Cross-cultural Adaptation",{"date":303,"type":35},{"date":637,"type":35},"2026-06-02",{"date":94,"type":23},{"name":41,"class":42},{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":18,"minAge":235,"maxAge":647,"enrollmentInfo":648,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":650,"conditions":651,"keywords":653,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":656,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":661,"locationsCount":43},"100625078","feasibility-and-reliability-of-integrating-electrically-evoked-stapedius-reflex-threshold-esrt-measurement-in-a-pediatric-cochlear-implant-programming-center-100625078","NCT07417956","Feasibility and Reliability of Integrating Electrically Evoked Stapedius Reflex Threshold (eSRT) Measurement in a Pediatric Cochlear Implant Programming Center","eSRT2","Inclusion Criteria:\n\n* Child aged 0 to 7 years\n* Unilateral or bilateral cochlear implant\n* Normal tympanogram\n* No objection from either parent or legal guardian\n\nExclusion Criteria:\n\n* Severe neurological disorder present before inclusion (identifiable by MRI and\u002For pediatric neurological assessment)\n* Unstable middle ear pathology on the day of inclusion (e.g., acute serous otitis, tympanic membrane perforation)\n* Documented abnormality or lesion of the facial nerve or stapedius muscle\n* Severe cognitive, psychiatric, or developmental delay at the day of inclusion\n* Family not fluent in oral French.","7 Years",{"count":649,"type":23},48,"In children aged 0 to 7 years, behavioral evaluation during cochlear implant programming is often difficult or unreliable. Objective, reproducible, and rapid markers are therefore essential. While objective measures such as ECAP (electrically evoked compound action potentials) help guide safe programming, they can show inter-electrode and inter-subject variability. Electrically evoked stapedius reflex threshold (eSRT) has emerged as a relevant objective marker to approximate the comfort level of stimulation.\n\nPediatric studies indicate that eSRT can be measured in the majority of children, closely corresponds to the comfort level, and is associated with improved speech outcomes when programming is guided by eSRT. In our previous single-center study in children aged 8 to 17 years (N=30; 44 implanted ears), eSRT was obtained in 83.3% of patients, with strong correlation between C-subjective and C-eSRT thresholds (r\\>0.94; p\\\u003C0.001) across all electrodes. Tonal performance remained stable, and speech intelligibility, particularly in noise (FraSiMat), significantly improved with an eSRT-based program after one month of habituation. Daily device use remained stable, reflecting good clinical acceptability. These results support the relevance of systematic integration of eSRT in routine programming.\n\nThe aim of the eSRT2 study is to evaluate the feasibility and reliability of eSRT measurement in real-world clinical care for children aged 0 to 7 years, and to monitor its stability during post-operative follow-up. Improved auditory accessibility and better-controlled acoustic comfort through eSRT are expected to accelerate speech development in children by enabling earlier improvements in vocal performance and intelligibility.",[652],"Hearing Loss in Children With Unilateral or Bilateral Cochlear Implants",[654,655],"Unilateral or bilateral cochlear implants","electrically evoked stapedius reflex threshold (eSRT)",{"date":303,"type":35},{"date":658,"type":35},"2026-06-15",{"date":660,"type":23},"2029-08-15",{"name":41,"class":42},{"id":663,"slug":664,"hasResults":12,"nctId":665,"briefTitle":666,"officialTitle":666,"acronym":667,"eligibilityCriteria":668,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":24,"phases":670,"briefSummary":671,"conditions":672,"keywords":674,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":677,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":681,"locationsCount":43},"100589066","risk-of-posterior-staphyloma-in-highly-myopic-europeans--from-epidemiology-to-anatomy-100589066","NCT06949579","Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.","MYOFORTE","Inclusion Criteria:\n\n* Adults with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with and without posterior staphyloma\n\n  * Adults aged 18 years or over\n  * Patient with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with good quality retinal imaging\n  * Patient who has signed a consent form to participate in the study\n  * Patient who is a beneficiary of a social security scheme or who is entitled to it\n\nExclusion Criteria:\n\n* Any systemic or ocular pathologies with an impact on the posterior segment of the eye\n\n  * Patient with a systemic pathology likely to affect the posterior segment of the eye:\n  * Diabetes\n  * Systemic inflammatory disease: sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, Horton's disease\n  * Patients with retinitis pigmentosa\n  * Patients with syndromic myopia\n  * Patients with myopia associated with a genetic disease such as hereditary vitreoretinopathy\n  * Patients under guardianship, curatorship or legal protection, as well as pregnant or breastfeeding women (article L1121-5 of the CSP).",{"count":22,"type":23},[181],"In this cross-sectionnal study the aim is to increase the understanding of posterior staphyloma through a unique European consortium. Therefore, all eligible patients that either visit the outpatient clinic at Radboud in Nimegen, the Netherlands, or visit University Hopital Puerta de HierroMajadahonda in Madrid, Spain, or visit University Hospital Cochin in Paris, France, and after consenting, will be included.\n\n600 high myopic European cases are expecting. A standardized protocol in all centers in order to create a uniform dataset.\n\nBesides the standard of care, blood samples will be collected.\n\nAll data collected will be stored in an onlie Castor database",[673],"High Myopia",[675,676],"High myopia","Myopic staphyloma",{"date":515,"type":35},{"date":679,"type":35},"2026-02-12",{"date":39,"type":23},{"name":41,"class":42},""]